Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3

Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, Staffan Nilsson, Kristina Nyström, Anna Martner, Magnus Lindh, Gunnar Norkrans, Johan Westin, Court Pedersen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Kristine Mørch, Peer Brehm Christensen, Martin Lagging – 13 January 2014 – The present study evaluated the impact of variations in the inosine triphosphate pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C virus (HCV) genotype 2/3 infection receiving peginterferon‐α2a and lower, conventional 800 mg daily dose of ribavirin.

Subscribe to